ASTELLAS PHARMA UNSP.ADR (YPHA) — Capital Reinvestment Ratio
ASTELLAS PHARMA UNSP.ADR (YPHA) has a Capital Reinvestment Ratio of 0.29x as of March 2025, meaning it reinvests 0% of its operating cash flow (€194.51 Billion) in capital expenditures (€57.33 Billion). Check how tangible is ASTELLAS PHARMA UNSP.ADR's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
ASTELLAS PHARMA UNSP.ADR Capital Reinvestment Ratio (2022–2025)
This chart tracks ASTELLAS PHARMA UNSP.ADR's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see YPHA operating cash flow.
Annual Capital Reinvestment Ratio for ASTELLAS PHARMA UNSP.ADR (2022–2025)
Year-by-year Capital Reinvestment Ratio for ASTELLAS PHARMA UNSP.ADR from 2022 to 2025. See YPHA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | €194.51 Billion | €57.33 Billion | ▼ -38.4% |
| 2024 | 0.48x | €172.47 Billion | €82.50 Billion | ▲ +77.1% |
| 2023 | 0.27x | €327.77 Billion | €88.54 Billion | ▼ -9.0% |
| 2022 | 0.30x | €257.44 Billion | €76.45 Billion | — |